Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia
Open Access
- 28 June 2024
- journal article
- research article
- Published by Springer Nature in Skeletal Radiology
- Vol. 54 (2) , 275-285
Abstract
Objective: Fatty infiltration of skeletal muscle (Myosteatosis) is associated with increased frailty, decreased muscle and mobility function, which seems fairly prevalent in multiple myeloma (MM) patients. This study aimed to determine the prognostic value of myosteatosis assessed by CT for progression-free survival (PFS) and overall survival (OS). Materials and methods: This IRB-approved cohort study included patients with newly diagnosed MM who were treated at a single university hospital and received CT at baseline. Geriatric assessment was performed via International Myeloma Working Group frailty score and Revised Myeloma Comorbidity Index. Myosteatosis was determined through measurement of paravertebral muscle radiodensity. Statistical analyses included uni- and multivariable Cox proportional hazard models and the Kaplan–Meier-method. Results: A total of 226 newly diagnosed MM patients (median age: 65 years [range: 29–89], 63% males, mean BMI: 25 [14–42]) were analyzed. The prevalence of myosteatosis was 51%. Muscle radiodensity was significantly decreased in individuals with International Staging System stage III vs. I (p < 0.001), indicating higher fatty muscle infiltration in patients with advanced disease. Both PFS and OS were significantly decreased in patients with myosteatosis (PFS: median 32.0 months (95% CI 20.5.5–42.2) vs. 66.4 months without myosteatosis (95% CI 42.5-not reached), p < .001); OS: median 58.6 (95% CI 51.3—90.2) vs. not reached, p < .001). Myosteatosis remained an independent predictor of OS in multivariable analyses (HR: 1.98; 95%-CI: 1.20–3.27). Conclusion: Myosteatosis seems fairly prevalent in patients with newly diagnosed MM and associated with impaired overall survival. Prospective clinical trials are required to better understand the role of myosteatosis in MM patients.Keywords
Funding Information
- Universitätsklinikum Freiburg
This publication has 50 references indexed in Scilit:
- Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myelomaCancer, 2022
- Characterizing cancer‐associated myosteatosis: anatomic distribution and cancer‐specific variability of low radiodensity muscleJCSM Rapid Communications, 2021
- Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2020
- A Sex‐Stratified Prognostic Nomogram Incorporating Body Compositions for Long‐Term Mortality in CirrhosisJournal of Parenteral and Enteral Nutrition, 2020
- Imaging of sarcopenia: old evidence and new insightsEuropean Radiology, 2019
- The evolution of body composition in oncology—epidemiology, clinical trials, and the future of patient care: facts and numbersJournal of Cachexia, Sarcopenia and Muscle, 2018
- Muscle radiodensity and mortality in patients with colorectal cancerCancer, 2018
- Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapyJournal of Cachexia, Sarcopenia and Muscle, 2016
- Prognostic Effect of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients With Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2016
- Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapiesCancer, 2013